Meridian Bioscience (VIVO) Gets a Buy Rating from H.C. Wainwright


H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Meridian Bioscience (VIVO) today and set a price target of $34.00. The company’s shares closed last Friday at $19.32.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 17.7% and a 47.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Meridian Bioscience has an analyst consensus of Moderate Buy, with a price target consensus of $34.00.

See today’s analyst top recommended stocks >>

Based on Meridian Bioscience’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $57.3 million and net profit of $9.36 million. In comparison, last year the company earned revenue of $50.25 million and had a net profit of $7.09 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts